nodes	percent_of_prediction	percent_of_DWPC	metapath
Flavoxate—Diphenidol—Benzphetamine—obesity	0.455	1	CrCrCtD
Flavoxate—PDE8B—islet of Langerhans—obesity	0.00478	0.0672	CbGeAlD
Flavoxate—PDE8A—islet of Langerhans—obesity	0.0043	0.0604	CbGeAlD
Flavoxate—Drowsiness—Phenylpropanolamine—obesity	0.00391	0.022	CcSEcCtD
Flavoxate—PDE7B—adipose tissue—obesity	0.00383	0.0538	CbGeAlD
Flavoxate—Palpitations—Methamphetamine—obesity	0.00359	0.0202	CcSEcCtD
Flavoxate—Palpitations—Benzphetamine—obesity	0.00347	0.0195	CcSEcCtD
Flavoxate—PDE7B—adrenal gland—obesity	0.00343	0.0483	CbGeAlD
Flavoxate—PDE8A—adrenal cortex—obesity	0.00341	0.0479	CbGeAlD
Flavoxate—PDE7A—endocrine gland—obesity	0.00341	0.0479	CbGeAlD
Flavoxate—Vision blurred—Phendimetrazine—obesity	0.00337	0.019	CcSEcCtD
Flavoxate—Drowsiness—Diethylpropion—obesity	0.00325	0.0183	CcSEcCtD
Flavoxate—Tachycardia—Methamphetamine—obesity	0.00324	0.0182	CcSEcCtD
Flavoxate—Palpitations—Phendimetrazine—obesity	0.00316	0.0178	CcSEcCtD
Flavoxate—Tachycardia—Benzphetamine—obesity	0.00312	0.0176	CcSEcCtD
Flavoxate—Drowsiness—Cimetidine—obesity	0.00309	0.0174	CcSEcCtD
Flavoxate—PDE8B—adipose tissue—obesity	0.00305	0.0429	CbGeAlD
Flavoxate—Tension—Phenylpropanolamine—obesity	0.003	0.0169	CcSEcCtD
Flavoxate—Nervousness—Phenylpropanolamine—obesity	0.00297	0.0167	CcSEcCtD
Flavoxate—Vision blurred—Phenylpropanolamine—obesity	0.00288	0.0162	CcSEcCtD
Flavoxate—Tension—Phentermine—obesity	0.00287	0.0161	CcSEcCtD
Flavoxate—Tachycardia—Phendimetrazine—obesity	0.00285	0.016	CcSEcCtD
Flavoxate—Nervousness—Phentermine—obesity	0.00284	0.016	CcSEcCtD
Flavoxate—PDE8A—pituitary gland—obesity	0.00275	0.0387	CbGeAlD
Flavoxate—PDE8A—adipose tissue—obesity	0.00274	0.0385	CbGeAlD
Flavoxate—PDE8B—adrenal gland—obesity	0.00273	0.0384	CbGeAlD
Flavoxate—PDE7B—liver—obesity	0.00268	0.0377	CbGeAlD
Flavoxate—Urticaria—Methamphetamine—obesity	0.00264	0.0148	CcSEcCtD
Flavoxate—Palpitations—Phentermine—obesity	0.00258	0.0145	CcSEcCtD
Flavoxate—Urticaria—Benzphetamine—obesity	0.00254	0.0143	CcSEcCtD
Flavoxate—Confusional state—Phenylpropanolamine—obesity	0.00251	0.0141	CcSEcCtD
Flavoxate—Tension—Diethylpropion—obesity	0.00249	0.014	CcSEcCtD
Flavoxate—PDE4D—adipose tissue—obesity	0.00248	0.0349	CbGeAlD
Flavoxate—Nervousness—Diethylpropion—obesity	0.00247	0.0139	CcSEcCtD
Flavoxate—PDE8A—adrenal gland—obesity	0.00246	0.0346	CbGeAlD
Flavoxate—Dry mouth—Phentermine—obesity	0.00243	0.0137	CcSEcCtD
Flavoxate—Tachycardia—Phenylpropanolamine—obesity	0.00243	0.0137	CcSEcCtD
Flavoxate—Vision blurred—Diethylpropion—obesity	0.0024	0.0135	CcSEcCtD
Flavoxate—PDE8B—endocrine gland—obesity	0.00237	0.0333	CbGeAlD
Flavoxate—Tachycardia—Phentermine—obesity	0.00233	0.0131	CcSEcCtD
Flavoxate—Leukopenia—Diethylpropion—obesity	0.00227	0.0128	CcSEcCtD
Flavoxate—Palpitations—Diethylpropion—obesity	0.00225	0.0126	CcSEcCtD
Flavoxate—PDE4D—adrenal gland—obesity	0.00223	0.0313	CbGeAlD
Flavoxate—Somnolence—Phenylpropanolamine—obesity	0.00221	0.0125	CcSEcCtD
Flavoxate—PDE4A—adipose tissue—obesity	0.0022	0.0309	CbGeAlD
Flavoxate—Leukopenia—Cimetidine—obesity	0.00216	0.0122	CcSEcCtD
Flavoxate—PDE8B—liver—obesity	0.00214	0.0301	CbGeAlD
Flavoxate—Dry mouth—Diethylpropion—obesity	0.00212	0.0119	CcSEcCtD
Flavoxate—Headache—Methamphetamine—obesity	0.00208	0.0117	CcSEcCtD
Flavoxate—PDE4B—islet of Langerhans—obesity	0.00206	0.0289	CbGeAlD
Flavoxate—Feeling abnormal—Phenylpropanolamine—obesity	0.00205	0.0116	CcSEcCtD
Flavoxate—Tachycardia—Diethylpropion—obesity	0.00202	0.0114	CcSEcCtD
Flavoxate—Headache—Benzphetamine—obesity	0.002	0.0113	CcSEcCtD
Flavoxate—Confusional state—Cimetidine—obesity	0.00199	0.0112	CcSEcCtD
Flavoxate—Raloxifene—ESR2—obesity	0.00198	0.359	CrCbGaD
Flavoxate—PDE4A—adrenal gland—obesity	0.00197	0.0277	CbGeAlD
Flavoxate—PDE4B—respiratory system—obesity	0.00194	0.0273	CbGeAlD
Flavoxate—Tachycardia—Cimetidine—obesity	0.00193	0.0108	CcSEcCtD
Flavoxate—PDE8A—liver—obesity	0.00192	0.027	CbGeAlD
Flavoxate—Nausea—Benzphetamine—obesity	0.0019	0.0107	CcSEcCtD
Flavoxate—Urticaria—Phentermine—obesity	0.00189	0.0107	CcSEcCtD
Flavoxate—Somnolence—Diethylpropion—obesity	0.00184	0.0104	CcSEcCtD
Flavoxate—Eosinophilia—Sibutramine—obesity	0.00184	0.0103	CcSEcCtD
Flavoxate—Headache—Phendimetrazine—obesity	0.00183	0.0103	CcSEcCtD
Flavoxate—Somnolence—Cimetidine—obesity	0.00175	0.00987	CcSEcCtD
Flavoxate—PDE4D—liver—obesity	0.00174	0.0245	CbGeAlD
Flavoxate—Nausea—Phendimetrazine—obesity	0.00173	0.00975	CcSEcCtD
Flavoxate—Feeling abnormal—Diethylpropion—obesity	0.00171	0.00962	CcSEcCtD
Flavoxate—Urticaria—Diethylpropion—obesity	0.00165	0.00927	CcSEcCtD
Flavoxate—Feeling abnormal—Cimetidine—obesity	0.00163	0.00915	CcSEcCtD
Flavoxate—Vomiting—Phenylpropanolamine—obesity	0.00158	0.00891	CcSEcCtD
Flavoxate—Vomiting—Phentermine—obesity	0.00152	0.00853	CcSEcCtD
Flavoxate—Headache—Phentermine—obesity	0.00149	0.0084	CcSEcCtD
Flavoxate—Nausea—Phenylpropanolamine—obesity	0.00148	0.00833	CcSEcCtD
Flavoxate—CHRM2—cardiovascular system—obesity	0.00148	0.0208	CbGeAlD
Flavoxate—Nausea—Phentermine—obesity	0.00142	0.00797	CcSEcCtD
Flavoxate—CHRM1—cardiovascular system—obesity	0.00134	0.0189	CbGeAlD
Flavoxate—Raloxifene—CYP19A1—obesity	0.00132	0.241	CrCbGaD
Flavoxate—Vomiting—Diethylpropion—obesity	0.00132	0.00742	CcSEcCtD
Flavoxate—PDE4B—pituitary gland—obesity	0.00132	0.0185	CbGeAlD
Flavoxate—PDE4B—adipose tissue—obesity	0.00131	0.0184	CbGeAlD
Flavoxate—Headache—Diethylpropion—obesity	0.0013	0.00731	CcSEcCtD
Flavoxate—Tension—Sibutramine—obesity	0.00127	0.00713	CcSEcCtD
Flavoxate—Vision blurred—Orlistat—obesity	0.00126	0.00708	CcSEcCtD
Flavoxate—Nervousness—Sibutramine—obesity	0.00125	0.00706	CcSEcCtD
Flavoxate—Vomiting—Cimetidine—obesity	0.00125	0.00706	CcSEcCtD
Flavoxate—Headache—Cimetidine—obesity	0.00124	0.00696	CcSEcCtD
Flavoxate—Nausea—Diethylpropion—obesity	0.00123	0.00693	CcSEcCtD
Flavoxate—Raloxifene—ESR1—obesity	0.00122	0.221	CrCbGaD
Flavoxate—Vision blurred—Sibutramine—obesity	0.00122	0.00685	CcSEcCtD
Flavoxate—Vertigo—Orlistat—obesity	0.0012	0.00675	CcSEcCtD
Flavoxate—Palpitations—Orlistat—obesity	0.00118	0.00664	CcSEcCtD
Flavoxate—PDE4B—adrenal gland—obesity	0.00118	0.0165	CbGeAlD
Flavoxate—Nausea—Cimetidine—obesity	0.00117	0.0066	CcSEcCtD
Flavoxate—Vertigo—Sibutramine—obesity	0.00116	0.00653	CcSEcCtD
Flavoxate—Leukopenia—Sibutramine—obesity	0.00116	0.00651	CcSEcCtD
Flavoxate—Palpitations—Sibutramine—obesity	0.00114	0.00642	CcSEcCtD
Flavoxate—Dry mouth—Orlistat—obesity	0.00111	0.00625	CcSEcCtD
Flavoxate—Tension—Bupropion—obesity	0.00111	0.00622	CcSEcCtD
Flavoxate—Nervousness—Bupropion—obesity	0.00109	0.00616	CcSEcCtD
Flavoxate—Dry mouth—Sibutramine—obesity	0.00108	0.00605	CcSEcCtD
Flavoxate—Confusional state—Sibutramine—obesity	0.00106	0.00598	CcSEcCtD
Flavoxate—Vision blurred—Bupropion—obesity	0.00106	0.00597	CcSEcCtD
Flavoxate—Skin disorder—Orlistat—obesity	0.00106	0.00596	CcSEcCtD
Flavoxate—Tachycardia—Sibutramine—obesity	0.00103	0.00579	CcSEcCtD
Flavoxate—Skin disorder—Sibutramine—obesity	0.00102	0.00576	CcSEcCtD
Flavoxate—PDE4B—endocrine gland—obesity	0.00102	0.0143	CbGeAlD
Flavoxate—Eosinophilia—Topiramate—obesity	0.00102	0.00574	CcSEcCtD
Flavoxate—CHRM2—endocrine gland—obesity	0.00101	0.0142	CbGeAlD
Flavoxate—Vertigo—Bupropion—obesity	0.00101	0.00569	CcSEcCtD
Flavoxate—Leukopenia—Bupropion—obesity	0.00101	0.00567	CcSEcCtD
Flavoxate—Palpitations—Bupropion—obesity	0.000995	0.0056	CcSEcCtD
Flavoxate—Antrafenine—PTGS2—obesity	0.000981	0.178	CrCbGaD
Flavoxate—Dry mouth—Bupropion—obesity	0.000938	0.00528	CcSEcCtD
Flavoxate—Somnolence—Sibutramine—obesity	0.000937	0.00527	CcSEcCtD
Flavoxate—Confusional state—Bupropion—obesity	0.000927	0.00522	CcSEcCtD
Flavoxate—CHRM1—endocrine gland—obesity	0.000922	0.013	CbGeAlD
Flavoxate—PDE4B—liver—obesity	0.000919	0.0129	CbGeAlD
Flavoxate—Feeling abnormal—Orlistat—obesity	0.000898	0.00505	CcSEcCtD
Flavoxate—Tachycardia—Bupropion—obesity	0.000897	0.00505	CcSEcCtD
Flavoxate—Skin disorder—Bupropion—obesity	0.000893	0.00502	CcSEcCtD
Flavoxate—Feeling abnormal—Sibutramine—obesity	0.000869	0.00489	CcSEcCtD
Flavoxate—Urticaria—Orlistat—obesity	0.000866	0.00487	CcSEcCtD
Flavoxate—Urticaria—Sibutramine—obesity	0.000838	0.00471	CcSEcCtD
Flavoxate—Somnolence—Bupropion—obesity	0.000817	0.0046	CcSEcCtD
Flavoxate—Feeling abnormal—Bupropion—obesity	0.000758	0.00426	CcSEcCtD
Flavoxate—Urticaria—Bupropion—obesity	0.00073	0.00411	CcSEcCtD
Flavoxate—Tension—Topiramate—obesity	0.000704	0.00396	CcSEcCtD
Flavoxate—Nervousness—Topiramate—obesity	0.000697	0.00392	CcSEcCtD
Flavoxate—Vomiting—Orlistat—obesity	0.000693	0.0039	CcSEcCtD
Flavoxate—Headache—Orlistat—obesity	0.000683	0.00384	CcSEcCtD
Flavoxate—Vision blurred—Topiramate—obesity	0.000676	0.00381	CcSEcCtD
Flavoxate—Vomiting—Sibutramine—obesity	0.00067	0.00377	CcSEcCtD
Flavoxate—Headache—Sibutramine—obesity	0.000661	0.00372	CcSEcCtD
Flavoxate—Nausea—Orlistat—obesity	0.000647	0.00364	CcSEcCtD
Flavoxate—Vertigo—Topiramate—obesity	0.000645	0.00363	CcSEcCtD
Flavoxate—Leukopenia—Topiramate—obesity	0.000642	0.00361	CcSEcCtD
Flavoxate—Palpitations—Topiramate—obesity	0.000634	0.00357	CcSEcCtD
Flavoxate—Nausea—Sibutramine—obesity	0.000626	0.00352	CcSEcCtD
Flavoxate—Dry mouth—Topiramate—obesity	0.000598	0.00336	CcSEcCtD
Flavoxate—Confusional state—Topiramate—obesity	0.000591	0.00332	CcSEcCtD
Flavoxate—Vomiting—Bupropion—obesity	0.000584	0.00329	CcSEcCtD
Flavoxate—Headache—Bupropion—obesity	0.000576	0.00324	CcSEcCtD
Flavoxate—Tachycardia—Topiramate—obesity	0.000572	0.00322	CcSEcCtD
Flavoxate—Skin disorder—Topiramate—obesity	0.000569	0.0032	CcSEcCtD
Flavoxate—Nausea—Bupropion—obesity	0.000546	0.00307	CcSEcCtD
Flavoxate—Somnolence—Topiramate—obesity	0.000521	0.00293	CcSEcCtD
Flavoxate—Feeling abnormal—Topiramate—obesity	0.000483	0.00272	CcSEcCtD
Flavoxate—Urticaria—Topiramate—obesity	0.000465	0.00262	CcSEcCtD
Flavoxate—Vomiting—Topiramate—obesity	0.000372	0.0021	CcSEcCtD
Flavoxate—Headache—Topiramate—obesity	0.000367	0.00206	CcSEcCtD
Flavoxate—Nausea—Topiramate—obesity	0.000348	0.00196	CcSEcCtD
Flavoxate—CHRM2—Signaling Pathways—CRH—obesity	1.14e-05	3.92e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PRKCD—obesity	1.14e-05	3.91e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3CD—obesity	1.13e-05	3.89e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SDC1—obesity	1.13e-05	3.87e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PRKCD—obesity	1.12e-05	3.86e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKR1C3—obesity	1.12e-05	3.86e-05	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—PIK3CA—obesity	1.12e-05	3.85e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PIK3CB—obesity	1.12e-05	3.85e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MTOR—obesity	1.12e-05	3.85e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—SERPINE1—obesity	1.12e-05	3.84e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MMP9—obesity	1.12e-05	3.84e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—HTR2A—obesity	1.11e-05	3.83e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—C3—obesity	1.11e-05	3.83e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKR1C3—obesity	1.11e-05	3.81e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—HTR2A—obesity	1.1e-05	3.78e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—PIK3CA—obesity	1.1e-05	3.78e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—C3—obesity	1.1e-05	3.78e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NPS—obesity	1.09e-05	3.76e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—TYK2—obesity	1.09e-05	3.74e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MAPK8—obesity	1.09e-05	3.74e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—AKT1—obesity	1.08e-05	3.72e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NPS—obesity	1.08e-05	3.71e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—RHOA—obesity	1.08e-05	3.71e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—F2—obesity	1.08e-05	3.7e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PRKCB—obesity	1.08e-05	3.7e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HTR2C—obesity	1.07e-05	3.69e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—DRD1—obesity	1.07e-05	3.69e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3R1—obesity	1.07e-05	3.67e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—NOS3—obesity	1.07e-05	3.67e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MTOR—obesity	1.06e-05	3.66e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PIK3CB—obesity	1.06e-05	3.66e-05	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—IL6—obesity	1.06e-05	3.66e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—F2—obesity	1.06e-05	3.65e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PRKCB—obesity	1.06e-05	3.65e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—DRD1—obesity	1.06e-05	3.64e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HTR2C—obesity	1.06e-05	3.64e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AGT—obesity	1.06e-05	3.63e-05	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—AKT1—obesity	1.06e-05	3.63e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NTRK2—obesity	1.04e-05	3.59e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AGT—obesity	1.04e-05	3.59e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ADRB1—obesity	1.04e-05	3.57e-05	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—AKT1—obesity	1.04e-05	3.57e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NTRK2—obesity	1.03e-05	3.54e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CG—obesity	1.03e-05	3.54e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ADRB1—obesity	1.03e-05	3.53e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—IL6—obesity	1.02e-05	3.51e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—GHRL—obesity	1.02e-05	3.5e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PARP1—obesity	1.02e-05	3.5e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—PIK3CA—obesity	1.02e-05	3.5e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CG—obesity	1.02e-05	3.49e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—DRD4—obesity	1.01e-05	3.47e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PARP1—obesity	1e-05	3.45e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GHRL—obesity	1e-05	3.45e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—DRD4—obesity	9.96e-06	3.42e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—STAT3—obesity	9.93e-06	3.41e-05	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—AKT1—obesity	9.89e-06	3.4e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3CB—obesity	9.85e-06	3.39e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MTOR—obesity	9.85e-06	3.39e-05	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—AKT1—obesity	9.82e-06	3.38e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—POMC—obesity	9.8e-06	3.37e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—F2—obesity	9.77e-06	3.36e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PRKCB—obesity	9.77e-06	3.36e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—IL6—obesity	9.73e-06	3.35e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MMP9—obesity	9.72e-06	3.34e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—POMC—obesity	9.67e-06	3.33e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PRKCB—obesity	9.64e-06	3.32e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—F2—obesity	9.64e-06	3.32e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CNR1—obesity	9.63e-06	3.31e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CNR1—obesity	9.51e-06	3.27e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TCF7L2—obesity	9.46e-06	3.25e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MAPK8—obesity	9.46e-06	3.25e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—AKT1—obesity	9.43e-06	3.24e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AKT2—obesity	9.42e-06	3.24e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—DRD2—obesity	9.4e-06	3.23e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CG—obesity	9.35e-06	3.21e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TCF7L2—obesity	9.34e-06	3.21e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—GCG—obesity	9.3e-06	3.2e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PTPN1—obesity	9.3e-06	3.2e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AKT2—obesity	9.3e-06	3.2e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—DRD2—obesity	9.28e-06	3.19e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MMP9—obesity	9.26e-06	3.18e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CG—obesity	9.23e-06	3.17e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—MYC—obesity	9.23e-06	3.17e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—TGFB1—obesity	9.21e-06	3.17e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PTPN1—obesity	9.18e-06	3.16e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GCG—obesity	9.18e-06	3.16e-05	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—AKT1—obesity	9.15e-06	3.14e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CD—obesity	9.05e-06	3.11e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—IL6—obesity	9e-06	3.1e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MAPK8—obesity	9e-06	3.09e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—AKT1—obesity	8.98e-06	3.09e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CD—obesity	8.93e-06	3.07e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—POMC—obesity	8.9e-06	3.06e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PRL—obesity	8.88e-06	3.05e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—POMC—obesity	8.78e-06	3.02e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PRL—obesity	8.76e-06	3.01e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—STK11—obesity	8.75e-06	3.01e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCL2—obesity	8.71e-06	2.99e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PLG—obesity	8.65e-06	2.97e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—STAT3—obesity	8.65e-06	2.97e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—RHOA—obesity	8.63e-06	2.97e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—STK11—obesity	8.63e-06	2.97e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCL2—obesity	8.6e-06	2.96e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MMP9—obesity	8.56e-06	2.94e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AKT2—obesity	8.55e-06	2.94e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3R1—obesity	8.55e-06	2.94e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PLG—obesity	8.54e-06	2.94e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—RHOA—obesity	8.52e-06	2.93e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AKT2—obesity	8.44e-06	2.9e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FOXO3—obesity	8.44e-06	2.9e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3R1—obesity	8.44e-06	2.9e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ADRB2—obesity	8.42e-06	2.89e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FOXO3—obesity	8.33e-06	2.87e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MAPK8—obesity	8.33e-06	2.86e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ADRB2—obesity	8.31e-06	2.86e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—AKT1—obesity	8.31e-06	2.86e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SOCS1—obesity	8.29e-06	2.85e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—STAT3—obesity	8.23e-06	2.83e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CD—obesity	8.22e-06	2.83e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SOCS3—obesity	8.19e-06	2.82e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SOCS1—obesity	8.19e-06	2.81e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CD—obesity	8.11e-06	2.79e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SOCS3—obesity	8.09e-06	2.78e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—MYC—obesity	8.03e-06	2.76e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—GNB3—obesity	8.02e-06	2.76e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—TGFB1—obesity	8.01e-06	2.76e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GNB3—obesity	7.92e-06	2.72e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—TYK2—obesity	7.91e-06	2.72e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CB—obesity	7.89e-06	2.71e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IGF2—obesity	7.88e-06	2.71e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—RHOA—obesity	7.84e-06	2.7e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—PIK3CA—obesity	7.83e-06	2.69e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—GNAS—obesity	7.81e-06	2.68e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—TYK2—obesity	7.8e-06	2.68e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CB—obesity	7.79e-06	2.68e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IGF2—obesity	7.77e-06	2.67e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3R1—obesity	7.76e-06	2.67e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—RHOA—obesity	7.74e-06	2.66e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—GNAS—obesity	7.71e-06	2.65e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3R1—obesity	7.66e-06	2.63e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—MYC—obesity	7.65e-06	2.63e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APOB—obesity	7.65e-06	2.63e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—TGFB1—obesity	7.63e-06	2.62e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—STAT3—obesity	7.61e-06	2.62e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APOB—obesity	7.55e-06	2.59e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCL5—obesity	7.47e-06	2.57e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCL5—obesity	7.37e-06	2.53e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—LPL—obesity	7.3e-06	2.51e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—FOXO1—obesity	7.25e-06	2.49e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—RPS6KB1—obesity	7.24e-06	2.49e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—LPL—obesity	7.21e-06	2.48e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CB—obesity	7.16e-06	2.46e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—FOXO1—obesity	7.15e-06	2.46e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—RPS6KB1—obesity	7.14e-06	2.46e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—MYC—obesity	7.08e-06	2.43e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CB—obesity	7.07e-06	2.43e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—TGFB1—obesity	7.06e-06	2.43e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—IL6—obesity	6.94e-06	2.39e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—PIK3CA—obesity	6.82e-06	2.34e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PRKCD—obesity	6.73e-06	2.31e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PRKCD—obesity	6.64e-06	2.28e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—HTR2A—obesity	6.58e-06	2.26e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—C3—obesity	6.57e-06	2.26e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—HTR2A—obesity	6.5e-06	2.23e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—PIK3CA—obesity	6.49e-06	2.23e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—C3—obesity	6.49e-06	2.23e-05	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—AKT1—obesity	6.4e-06	2.2e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IRS2—obesity	6.25e-06	2.15e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AGT—obesity	6.25e-06	2.15e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IRS2—obesity	6.17e-06	2.12e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AGT—obesity	6.17e-06	2.12e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—LEP—obesity	6.12e-06	2.1e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APOE—obesity	6.12e-06	2.1e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CAV1—obesity	6.06e-06	2.08e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—APOA1—obesity	6.05e-06	2.08e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APOE—obesity	6.04e-06	2.08e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—LEP—obesity	6.04e-06	2.08e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—IL6—obesity	6.04e-06	2.08e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—PIK3CA—obesity	6.01e-06	2.07e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CAV1—obesity	5.99e-06	2.06e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—APOA1—obesity	5.97e-06	2.05e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ESR1—obesity	5.84e-06	2.01e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—F2—obesity	5.77e-06	1.98e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PRKCB—obesity	5.77e-06	1.98e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ESR1—obesity	5.77e-06	1.98e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IL6—obesity	5.75e-06	1.98e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—BAD—obesity	5.7e-06	1.96e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PRKCB—obesity	5.7e-06	1.96e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—F2—obesity	5.7e-06	1.96e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—BAD—obesity	5.63e-06	1.94e-05	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—AKT1—obesity	5.57e-06	1.92e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CG—obesity	5.52e-06	1.9e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IRS1—obesity	5.46e-06	1.88e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CG—obesity	5.45e-06	1.87e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IRS1—obesity	5.39e-06	1.85e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IL6—obesity	5.32e-06	1.83e-05	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—AKT1—obesity	5.3e-06	1.82e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—POMC—obesity	5.26e-06	1.81e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—INS—obesity	5.23e-06	1.8e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—POMC—obesity	5.19e-06	1.78e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—INS—obesity	5.16e-06	1.77e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCL2—obesity	5.14e-06	1.77e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCL2—obesity	5.08e-06	1.75e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IGF1—obesity	5.06e-06	1.74e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKT2—obesity	5.05e-06	1.74e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IGF1—obesity	4.99e-06	1.72e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKT2—obesity	4.99e-06	1.71e-05	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—AKT1—obesity	4.91e-06	1.69e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CD—obesity	4.85e-06	1.67e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—PIK3CA—obesity	4.81e-06	1.65e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—SERPINE1—obesity	4.8e-06	1.65e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CD—obesity	4.79e-06	1.65e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—PIK3CA—obesity	4.75e-06	1.63e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—SERPINE1—obesity	4.74e-06	1.63e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TYK2—obesity	4.67e-06	1.61e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—RHOA—obesity	4.63e-06	1.59e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TYK2—obesity	4.61e-06	1.59e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3R1—obesity	4.58e-06	1.58e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—NOS3—obesity	4.58e-06	1.58e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—RHOA—obesity	4.57e-06	1.57e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—NOS3—obesity	4.53e-06	1.56e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3R1—obesity	4.53e-06	1.56e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—PIK3CA—obesity	4.37e-06	1.5e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—PIK3CA—obesity	4.31e-06	1.48e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CB—obesity	4.23e-06	1.45e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MTOR—obesity	4.23e-06	1.45e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MTOR—obesity	4.18e-06	1.44e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CB—obesity	4.18e-06	1.44e-05	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—AKT1—obesity	3.93e-06	1.35e-05	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—AKT1—obesity	3.88e-06	1.33e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL6—obesity	3.87e-06	1.33e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL6—obesity	3.82e-06	1.31e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MMP9—obesity	3.68e-06	1.26e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MMP9—obesity	3.63e-06	1.25e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MAPK8—obesity	3.58e-06	1.23e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—AKT1—obesity	3.57e-06	1.23e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MAPK8—obesity	3.53e-06	1.21e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—AKT1—obesity	3.52e-06	1.21e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—STAT3—obesity	3.27e-06	1.12e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—STAT3—obesity	3.23e-06	1.11e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—MYC—obesity	3.04e-06	1.04e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—TGFB1—obesity	3.03e-06	1.04e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—MYC—obesity	3e-06	1.03e-05	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—TGFB1—obesity	2.99e-06	1.03e-05	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—PIK3CA—obesity	2.58e-06	8.87e-06	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—PIK3CA—obesity	2.55e-06	8.76e-06	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL6—obesity	2.28e-06	7.85e-06	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL6—obesity	2.25e-06	7.75e-06	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—AKT1—obesity	2.11e-06	7.25e-06	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—AKT1—obesity	2.08e-06	7.15e-06	CbGpPWpGaD
